Holen Sie sich die Stockscreener-App
14.30
6.47%
-0.99
Handel nachbörslich:
14.30
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Polyrizon Announces GMP Manufacturing of Clinical Trial Material with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - marketscreener.com
Polyrizon completes GMP batch for intranasal product trial By Investing.com - Investing.com South Africa
Aug Intraday: Does Polyrizon Ltd have strong fundamentalsRate Hike & AI Optimized Trade Strategies - baoquankhu1.vn
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - Bitget
Polyrizon Completes GMP Clinical Material for Planned U.S. Intranasal Study - TipRanks
Polyrizon completes GMP batch for intranasal product trial - Investing.com
Polyrizon makes GMP batch for planned U.S. nasal allergy, virus trial - Stock Titan
What catalysts could drive Polyrizon Ltd. stock higher2026 Price Swings & Daily Price Action Insights - Naître et grandir
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PLRZ Should I Buy - Intellectia AI
Polyrizon reports nasal deposition study results for naloxone By Investing.com - Investing.com Australia
Polyrizon reports nasal deposition study results for naloxone - Investing.com
Polyrizon Reports Superior Nasal Deposition for Naloxone Formulation in Comparative Study - TipRanks
Polyrizon (Nasdaq: PLRZ) reports enhanced naloxone nasal deposition study - Stock Titan
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product - marketscreener.com
Lab test: Polyrizon nasal naloxone hits target area 94.6% vs 79.6% - Stock Titan
PLRZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
S&P 500 Gains 1%; April Jobs Top Expectations - Intellectia AI
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker - Yahoo Finance
Polyrizon Ltd. announces $4.97 million securities offering - MSN
Polyrizon recives Nasdaq delisting notice - MSN
PLRZ Technical Analysis & Stock Price Forecast - Intellectia AI
Is Polyrizon Ltd. stock a value trapJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
Polyrizon signs MOU to acquire 51% stake in Arrow Aviation By Investing.com - Investing.com South Africa
Polyrizon stock rises on potential acquisition of Arrow Aviation - Investing.com
Will Polyrizon Ltd. stock hit new highs in YEARQuarterly Trade Report & Smart Money Movement Tracker - mfd.ru
How Polyrizon Ltd. stock benefits from tech adoptionWeekly Stock Report & Weekly High Return Opportunities - mfd.ru
Polyrizon stock rises on potential acquisition of Arrow Aviation By Investing.com - Investing.com Canada
Polyrizon intends to secure controlling stake in profitable private jet operator - marketscreener.com
Polyrizon signs MOU to acquire 51% stake in Arrow Aviation - Investing.com
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator - The Manila Times
Biotech Polyrizon lines up $5.8M deal for $19M private jet firm - Stock Titan
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock: Partners With Polyrizon to Advance Intranasal MEAI Therapy - parameter.io
Polyrizon climbs on Clearmind Deal - Baystreet.ca
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal - Investing.com India
Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI - TipRanks
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation - The Manila Times
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Inc. Partners with Polyrizon Ltd. to Develop Innovative Intranasal Formulation for MEAI in CNS Disorders - Quiver Quantitative
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic ... - Caledonian Record
Biotechs team up on intranasal, non-hallucinogenic addiction therapy - Stock Titan
Polyrizon shares gain on plan to buy majority stake in private aviation company - MSN
Polyrizon Signs MOU to Acquire 51% Stake in Arrow Aviation - Intellectia AI
Polyrizon Moves to Acquire 51% Stake in Global Private Aviation Firm Arrow Aviation - TipRanks
Polyrizon stock rises after announcing plan to acquire stake in private aviation firm - Investing.com Nigeria
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):